August 2021: Ka dib markii ay ku guuldareysteen ugu yaraan laba khad oo hore ee daaweynta nidaamka, Maamulka Cuntada iyo Dawooyinka ayaa oggolaaday belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), kinase inhibitor, oo loogu talagalay dadka waaweyn iyo bukaan-socodka carruurta 12 sano iyo ka weyn oo leh cudur-ku-tallaal-ku-soo-horjeeda (GVHD dabadheeraad ah).
KD025-213 (NCT03640481), oo ah kala-sooc, calaamad furan, tijaabo qaddar badan leh oo 65 bukaan oo qaba GVHD dabadheeraad ah lagu daweeyay belumosudil 200 mg afka laga maamulo hal mar maalintii, ayaa loo adeegsaday in lagu qiimeeyo waxtarka.
The overall response rate (ORR) through Cycle 7 Day 1 was the primary efficacy end measure, with overall response defined as a full response (CR) or partial response (PR) according to the 2014 NIH Consensus Development Project on Clinical Trials in Chronic Graft-versus-Host Disease guidelines. The ORR was 75% (95 percent CI: 63, 85); 6% of patients had a complete response, and 69 percent had a partial response. The average time it took to get a first answer was 1.8 months (95 percent CI: 1.0, 1.9). The median duration of response for chronic GVHD was 1.9 months, measured from first response through progression, death, or new systemic treatments (95 percent CI: 1.2, 2.9). No mortality or new systemic medication initiation occurred in 62 percent (95 percent CI: 46, 74) of patients who achieved response for at least 12 months after response.
Infekshannada, asthenia, lallabbo, shuban, dyspnea, qufac, edoema, dhiig -bax, calool xanuun, muruqyada, madax -xanuun, fosfate -ka ayaa yaraaday, gudbinta gamma glutamyl ayaa kordhay, lymphocytes ayaa hoos u dhacday, dhiig -karku wuxuu ahaa falcelinta ugu xun (20%), oo ay ku jiraan shaybaar aan caadi ahayn.
Belumosudil waa in la qaataa hal mar maalintii, cuntada, qiyaas 200 mg ah.
